GDTC
Income statement / Annual
Last year (2023), CytoMed Therapeutics Limited's total revenue was $290,560.00,
an increase of 7.48% from the previous year.
In 2023, CytoMed Therapeutics Limited's net income was -$3.13 M.
See CytoMed Therapeutics Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$290,560.00 |
$270,335.15 |
$84,178.36 |
$44,923.61 |
$0.00 |
| Cost of Revenue |
$77,469.00
|
$6,477.73
|
$2,590.99
|
$3,496.11
|
$0.00
|
| Gross Profit |
$213,091.00
|
$263,857.42
|
$81,587.37
|
$41,427.51
|
$0.00
|
| Gross Profit Ratio |
0.73
|
0.98
|
0.97
|
0.92
|
0
|
| Research and Development Expenses |
$1.20 M
|
$1.13 M
|
$806,448.09
|
$784,199.89
|
$323,983.71
|
| General & Administrative Expenses |
$344,254.00
|
$443,290.45
|
$433,474.08
|
$112,323.39
|
$0.00
|
| Selling & Marketing Expenses |
$25,239.00
|
$0.00
|
$1,834.55
|
$4,670.79
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.93 M
|
$443,290.45
|
$435,308.63
|
$116,994.18
|
$29,722.91
|
| Other Expenses |
$0.00
|
-$195,323.52
|
$36,127.46
|
$47,809.34
|
$0.00
|
| Operating Expenses |
$3.12 M
|
$1.38 M
|
$1.28 M
|
$949,003.41
|
$451,037.86
|
| Cost And Expenses |
$3.20 M
|
$1.38 M
|
$1.28 M
|
$949,003.41
|
$451,037.86
|
| Interest Income |
$38,728.00
|
$1,557.77
|
$2,491.17
|
$79,711.69
|
$20,057.85
|
| Interest Expense |
$0.00
|
$92,987.32
|
$87,028.89
|
$79,711.69
|
$0.00
|
| Depreciation & Amortization |
$77,469.00
|
$291,844.62
|
$243,924.33
|
$220,986.74
|
$97,225.17
|
| EBITDA |
-$2.94 M |
-$1.11 M |
-$1.19 M |
-$728,016.67 |
-$349,624.64 |
| EBITDA Ratio |
-10.11
|
-4.11
|
-14.12
|
-16.21
|
0
|
| Operating Income Ratio |
-10.02
|
-5.19
|
-17.02
|
-21.12
|
0
|
| Total Other Income/Expenses Net |
-$219,504.00
|
-$922,479.55
|
-$320,958.24
|
-$513,216.86
|
-$19,102.54
|
| Income Before Tax |
-$3.13 M
|
-$2.33 M
|
-$1.53 M
|
-$1.47 M
|
-$465,952.34
|
| Income Before Tax Ratio |
-10.78
|
-8.6
|
-18.22
|
-32.66
|
0
|
| Income Tax Expense |
$373.69
|
$1,218.29
|
-$53,427.35
|
$84,709.58
|
$0.00
|
| Net Income |
-$3.13 M
|
-$2.40 M
|
-$1.53 M
|
-$1.47 M
|
-$465,952.34
|
| Net Income Ratio |
-10.78
|
-8.87
|
-18.22
|
-32.66
|
0
|
| EPS |
-0.29 |
-0.30457 |
-0.22183 |
-0.24929 |
-0.08102097 |
| EPS Diluted |
-0.29 |
-0.30457 |
-0.22183 |
-0.24929 |
-0.08102097 |
| Weighted Average Shares Out |
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Weighted Average Shares Out Diluted |
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Link |
|
|
|
|
|
